Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity

Gastrointestinal stromal tumors (GISTs) are rare and current estimates range from 4,000 to 6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has shown a survival benefit in GISTs, and the presence of KIT mutation status is predictive of response. The current case...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghias, Adnan Asif Parvez, Bhayani, Shahzeem, Gemmel, David J., Garg, Sudershan K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906758/
https://www.ncbi.nlm.nih.gov/pubmed/29686796
http://dx.doi.org/10.1080/20009666.2018.1454787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906758/
https://www.ncbi.nlm.nih.gov/pubmed/29686796
http://dx.doi.org/10.1080/20009666.2018.1454787

Ejemplares similares